Krishna Kodukula

Based in SRI International’s Shenandoah Valley, Va., location, Krishna Kodukula, Ph.D., focuses on practical applications of proteomics to create new diagnostics, therapeutics and vaccines for infectious diseases and biodefense. His current work involves understanding biological function at a system level, specifically studying host-pathogen interactions to help discover new markers and therapies for infectious, orphan and neglected diseases.

Previously, Kodukula was the technical lead of a national program to develop technologies and strategies for reducing drug discovery and development time during national emergencies. Prior to that, he helped launch Small Molecule Therapeutics, co-founded Pyxis Technology Solutions and also worked at Bristol-Myers Squibb Pharmaceutical Research Institute and the Roche Institute of Molecular Biology, Hoffman-La Roche.

Kodukula received his Ph.D. in biochemistry and botany from Utkal University, Bhubaneswar, India. He completed postdoctoral work at the Indian Institute of Science, where he was a National Biotechnology Board Fellow. He is a member of the American Society for Biochemistry and Molecular Biology, Society for Biomolecular Sciences and NIAID/NIH special panel on research and development for biodefense applications. He has also served on review committees since 2004.